Immunis, Inc. | MedPath

Immunis Secures $25 Million to Advance IMM01-STEM in Phase 2 Trials for Age-Related Muscle Loss

4 months ago

• Immunis has successfully closed a $25 million Series A-1 financing round to support the clinical development of IMM01-STEM. • The funding will enable Immunis to initiate two Phase 2 clinical trials evaluating IMM01-STEM for muscle loss and metabolic dysfunction in elderly individuals. • A previous Phase 1/2a trial demonstrated the safety and tolerability of IMM01-STEM, with patients showing improvements in physical function and gait speed. • Preclinical studies suggest IMM01-STEM can reverse muscle atrophy and improve metabolic function, positioning it as a promising therapy for age-related conditions.

Immunis' IMMUNA Receives FDA Clearance for Phase II Sarcopenic Obesity Trial

8 months ago

• Immunis has received FDA clearance for a Phase II clinical trial of IMMUNA, a secretome therapy targeting sarcopenic obesity. • The trial aims to assess IMMUNA's efficacy in improving mobility and independence in individuals affected by sarcopenic obesity. • IMMUNA is designed to reduce fat while preserving muscle mass, contrasting with GLP-1 drugs that may lead to muscle loss. • Preclinical data supports IMMUNA's potential to increase lean mass, reduce fat mass, and enhance muscle function.